Gynecologic Cancers | Clinical

March 04, 2021

The FDA has accepted a New Drug Application for pafolacianine sodium injection and granted it Priority Review as a potential adjunct for identifying ovarian cancer during surgery.

February 23, 2021

Shana Wingo, MD, talks about the challenges of treating patients in the Greater Phoenix, Arizona area.

February 23, 2021

A novel DNA-mediated interleukin-12 immunotherapy, GEN-1, had been granted a Fast Track designation by the FDA for the treatment of advanced ovarian cancer.

February 14, 2021

The team of oncologic professionals at New Jersey’s only NCI-Designated Comprehensive Cancer Center, Rutgers Cancer Institute, has been expanded to include a new chief of gynecologic oncology.

February 12, 2021

A Biologics License Application was submitted to the FDA for tisotumab vedotin as treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

January 21, 2021

Investigators treating patients with gynecologic malignancies are optimistic that multiple clinical trials exploring new second-line cervical cancer treatments will result in a much-anticipated breakthrough for the field.

January 08, 2021

Noelle G. Cloven, MD, discussed the current cervical cancer treatment paradigm, the unmet needs that still remain to be addressed, and encouraging new directions of research in clinical trials in honor of Cervical Cancer Awareness Month.

January 06, 2021

VGX-3100, a therapeutic DNA vaccine, achieved a 25% reduction or more reduction in HPV-16/18-associated vulvar high-grade squamous intraepithelial lesion in 63% of patients at 6 months after treatment with the agent, according to findings from an open-label phase 2 clinical trial.

January 02, 2021

During a Targeted Oncology Case Based Peer Perspectives event, Bradley Monk, MD, discussed how the use of molecular testing can improve treatment decisions for ovarian cancer.

December 25, 2020

During a Targeted Oncology Case Based Peer Perspectives event, John K. Chan, MD, reviewed the case of a 49-year-old African American woman with high-grade epithelial ovarian cancer.